Title
Category
Credits
Event date
Cost
Bupe...There it is! Part I - Prescribing Basics | Palliative Care Educational Series (RECORDING)
  • Palliative Care
  • Buprenorphine
  • Opioid Use Disorder (OUD)
  • Pain Management
  • 1.00 AMA PRA Category 1 Credit™
$0.00
In this recorded Palliative Care Educational Series presentation, palliative care and addiction medicine specialist Dr. Janet Ho provides a comprehensive overview on the use of buprenorphine, a partial opioid agonist, for pain management and treatment of opioid use disorder. Dr. Ho begins with an overview of buprenorphine's pharmacology, including its unique properties as a partial agonist with a strong binding affinity to the mu-opioid receptor, its ceiling effect on respiratory depression, and its ability to reduce hyperalgesia and cravings. Dr.
Buprenorphine Mini Course: Building on Federal Prescribing Guidance
  • Buprenorphine
  • 2.00 AMA PRA Category 1 Credit™
$0.00
This 2-hour mini course for medical providers, clinicians, and students reviews prescribing buprenorphine to patients with opioid use disorder and is presented by ASAM in collaboration with the American Medical Association (AMA) and Shatterproof.
Buprenorphine Prescribing for Opioid Use Disorder in Primary Care
  • Buprenorphine
  • Opioid Use Disorder (OUD)
  • 0.50 AMA PRA Category 1 Credit™
$0.00
The X-Waiver is gone! This educational activity will show you how to incorporate buprenorphine prescribing for opioid use disorder into your clinical practice.Rhode Island Specific: This course qualifies for 0.5 hours of risk management credit.
ORN Fall 2023 - The Evolution of Buprenorphine: Prescribing practices and efforts to increase MOUD access
  • Buprenorphine
  • Opioid Use Disorder (OUD)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 AOA Category 1-A
$0.00
This talk will describe the distribution of buprenorphine patient caseloads for clinicians prescribing formulations of buprenorphine indicated to treat opioid use disorder, how those caseloads evolve over time, and factors associated higher-volume buprenorphine prescribers. The presentation will also discuss implications for expanding access to medication treatment for opioid use disorder and state and federal policy efforts.